

Special Issue

Immunotherapy for Hematologic Malignancies

Message from the Guest Editor

Hematological malignancies present some unique challenges like disease heterogeneity, drug resistance leading to relapse and persistence of minimal residual disease, and the emergent immunosuppressive microenvironment resulting in sanctuary sites within the bone marrow. The introduction of immunotherapy either in the form of immunomodulators, checkpoint inhibitors, immune cell engagers like bispecific T cell engagers (BiTEs), or Chimeric Antigen Receptor (CAR)-T cell therapy has heralded a new era in combating hematological malignancy. The present issue will focus on studies trying to delineate the process of emergence of the immunosuppressive environment and the advancements made in immune therapy to overcome this hurdle. The emphasis will be on capturing the different approaches utilized to increase the immune-based tools available to improve patient outcomes in hematological malignancy. Areas of interest will include multitargeted approaches in overcoming immune evasion, tumor vaccination, and preventive measures utilized to decrease toxicity, especially immune-related adverse effects.

Guest Editor

Dr. Rajesh Ramakrishnan Nair

Investigational Drug Services, Moffitt Cancer Center, Tampa, FL, USA

Deadline for manuscript submissions

15 August 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/248044

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)